• Immune Therapy Technology Platform

    A traditional plasmid DNA vaccine has several limitations as antigen expressing vehicles. It not only poorly enters cells of the body but also inside the cell it undergoes rapid degradation by the nucleases or by the low pH of the endosomes. Viral vectors have been developed to improve cellular delivery of DNA-encoded antigens because viruses have evolved and efficiently enter into cells to overcome the cellular degradations and to express their genetic materials. Viral vector-based vaccines present significant manufacturing and safety challenges compared to plasmid DNA, and their repeated administration is restricted due to vector immunity.

    Genetic Immunity's Nanomedicine formulation has been specifically developed for pathogen-like formulations of plasmid DNA-encoded antigens to improve their stability and immunogenicity.

    The Nanomedicine plasmid DNA combines the advantages of both viral vector-based and plasmid DNA vaccines. It utilizes chemical excipients to form a pathogen-like nanoparticle with features similar to the viruses. PEIm (mannosylated polymer) is a novel excipient in our nanoformulation that facilitates the cellular uptake and the transfer of antigens into the cytoplasm and nucleus of the cells required for efficient antigen expression. Nanomedicine formulated antigens can be manufactured with consistency in large quantity and administered repeatedly because the antigen only contains formulation excipients in addition to the disease-specific antigens.

    Our Nanomedicine formulations are particularly attractive for the delivery of nucleic acids due to excellent safety features and transfection efficiency. Because of this Nanomedicine can provide a solution to the formulation, manufacturing and regulatory challenges of vaccines.

    The following is an illustration of the pathogen-like mechanism of entry, antigen expression and antigen presentation achieved with Nanomedicine